CLDF-GHAPP Podcast Series: MASH
4 Part Series
Hosted by: Nadege Gunn, MD
With Special Guests: Elizabeth Goacher, PA, and Ann Moore, NP
Related Podcast
![](https://novemhc.s3.amazonaws.com/mashaliance-media/99856094NewlyTherapy_Thumbnail.jpg)
Part 1 - Incorporating the Newly Approved Therapy for MASH into Practice
2024
![](https://novemhc.s3.amazonaws.com/mashaliance-media/2011626562WhatWeDontKnow_Thumbnail.jpg)
Part 4 - MASH- What We Don't Know, What We Want to Know
2024
![](https://novemhc.s3.amazonaws.com/mashaliance-media/1888491625SH_4_.png)
What is MASH?
2025
![](https://novemhc.s3.amazonaws.com/mashaliance-media/170945431AwaysMajor_Thumbnail.jpg)
Key Takeaways - Major Advancements In The Management of MASH with Parvez, Mantry, MD
2024
![](https://novemhc.s3.amazonaws.com/mashaliance-media/1756443434reated.png)
What Are the Consequences of MASH Going Untreated?
2025
![](https://novemhc.s3.amazonaws.com/mashaliance-media/1024520327ds_3_.png)
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2025
![](https://novemhc.s3.amazonaws.com/mashaliance-media/1280476198es_2_.png)
What Is the Clinical Profile of Resmetirom, Including Dosing Schedules?
2025
![](https://novemhc.s3.amazonaws.com/mashaliance-media/1113041723EducationAppCommunity_Thumbnail.jpg)
Part 3 - Strategies for Educating the APP Community on MASH
2024
![](https://novemhc.s3.amazonaws.com/mashaliance-media/802976785f_MASH.png)
GHAPPcast: Recognizing the Severity of MASH
2025
![](https://novemhc.s3.amazonaws.com/mashaliance-media/39451843bnail_.png)
How Is MASH Severity Staged? What Would an Ideal MASH NIT Algorithm Look Like?
2025